Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
1‐Year survival rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Response rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in grade III or IV renal toxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival (OS) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
1‐Year survival rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to higher objective response rate (ORR) compared with platinum combination (moderate certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).
1 finding from 1 review
QoL · non‐small cell lung cancer in the elderly population
1 finding from 1 review
1‐Year survival rate (OS1y) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower 1‐Year survival rate (OS1y) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower progression‐free survival compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher objective response rate (ORR) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review